Solid Tumor Treatment

Our solid tumor treatment product SPI-1620 has been licensed to Spectrum Pharmaceuticals, Inc. (NASDAQ - SPPI) for world-wide distribution. Spectrum is studying the molecule as an adjunct therapy of chemotherapy to direct more of the cytotoxic agent to the tumor and minimize the toxicity to normal organs. The product is currently in U.S. FDA Phase I clinical trials.

SPI-1620 is a highly selective peptide agonist of endothelin-B receptors, which can stimulate receptors on endothelial cells, the innermost layer of cells lining the blood vessels. This technology takes advantage of the fact that the blood supply to tumors is different than the blood supply to healthy organs. Blood vessels in the growing part of tumors are relatively devoid of smooth muscle covering and are rich in endothelial cells. Therefore, by stimulating the endothelial-B receptors present on the endothelial cells, SPI-1620 should selectively increase tumor blood flow, including breast, lung, and prostate tumors, while sparing healthy tissue. SPI-1620 is being developed as an adjunct to chemotherapy. In pre-clinical studies, when anti-cancer drugs, such as paclitaxel injection, are administered shortly after SPI-1620, the anti-cancer drug concentration in the tumor is increased several fold.

	Research		PreClinical		Clinical		Market
ENDG4020 Solid tumor treatment